A retrospective cohort study investigating synergism of air pollution and corticosteroid exposure in promoting cardiovascular and thromboembolic events in older adults

Kevin P. Josey, PhD[1]; Rachel C. Nethery, PhD[1]; Aayush Visaria, MD MPH[2]; Benjamin Bates, MD[2,4]; Poonam Gandhi, MS[2]; Ashwaghosha Parthasarathi, MBBS[2]; Melanie Rua, PharmD MPH[2]; David Robinson, PhD[3]; and Soko Setoguchi, MD DrPH[2,4,*]

[1] Department of Biostatistics, Harvard T.H. Chan School of Public Health, 655 Huntington Avenue, Building 2, 4th Floor, Boston, MA 02115, USA

[2] Rutgers University Institute for Health, Healthcare Policy, and Aging Research, The State University of New Jersey, 112 Paterson Street, New Brunswick, NJ 08901, USA

[3] Department of Geography, Rutgers University, 54 Joyce Kilmer Avenue, Piscataway, NJ 08854, USA

[4] Department of Medicine, Rutgers Robert Wood Johnson Medical School, One Robert Wood Johnson Place, New Brunswick, NJ 08901, USA

* Rutgers University Institute for Health, Healthcare Policy, and Aging Research
  112 Paterson Street, Room 402
  New Brunswick, NJ 08901, USA
  Phone: (848) 932-6507
  Email: soko.setoguchi@rutgers.edu

Abstract

Objective: To evaluate the synergistic effects created by fine particulate matter ($PM_{2.5}$) and corticosteroid use on hospitalization and mortality in older adults at high-risk for cardiovascular thromboembolic events (CTEs).

Design and Setting: A retrospective cohort study using a US nationwide administrative healthcare claims database.

Participants: A 50% random sample of participants with high-risk conditions for CTE from the 2008-2016 Medicare Fee-for-Service population.

Exposures: Corticosteroid therapy and seasonal-average $PM_{2.5}$.

Main Outcome Measures: Incidences of myocardial infarction or acute coronary syndrome, ischemic stroke or transient ischemic attack, heart failure, venous thromboembolism, atrial fibrillation, and all-cause mortality. We assessed additive interactions between $PM_{2.5}$ and corticosteroids using estimates of the relative excess risk due to interaction (RERI) obtained using marginal structural models for causal inference.

Results: Among the 1,936,786 individuals in the high CTE risk cohort (mean age 76.8, 40.0% male, 87.4% White), the mean $PM_{2.5}$ exposure level was 8.3 ± 2.4 $\mu g/m^3$ and 37.7% had at least one prescription for a systemic corticosteroid during follow-up. For all outcomes, we observed increases in risk associated with corticosteroid use and with increasing $PM_{2.5}$ exposure. $PM_{2.5}$ demonstrated a non-linear relationship with some outcomes. We also observed evidence of an interaction existing between corticosteroid use and $PM_{2.5}$ for some CTEs. For an increase in $PM_{2.5}$ from 8 $\mu g/m^3$ to 12 $\mu g/m^3$ (a policy-relevant change), the RERI of corticosteroid use and $PM_{2.5}$ was significant for heart failure (15.6%, 95% CI: 4.0%-27.3%). Increasing $PM_{2.5}$ from 5 $\mu g/m^3$ to 10 $\mu g/m^3$ yielded significant RERIs for incidences of heart failure (32.4; 95% CI: 14.9%-49.9%) and myocardial infarction/acute coronary syndromes (29.8%; 95% CI: 24.8%-54.0%).

Conclusion: $PM_{2.5}$ and systemic corticosteroid use were independently associated with increases in CTE hospitalizations. We also found evidence of significant additive interactions between the two exposures for heart failure and myocardial infarction/acute coronary syndromes suggesting synergy between these two exposures.

Strengths and Limitations of this Study

- We conduct analyses using robust causal inference and machine learning techniques and incorporate a large set of individual-level factors that are typically absent in environmental health analyses with large claims data sets.
- We present statistics that evaluate the synergy between fine particulate matter and corticosteroid therapy on the additive scale, which is more relevant for assessing excess risks and informing policy.
- Patient medical history prior to receiving Medicare benefits is unknowable within a Fee-for-Service claims database, which may lead to exclusion of some high-risk individuals from the cohort.
- We censor participants after the earlier of the end of first corticosteroid regimen or the first incidence of the outcome of interest, which makes the analyses statistically tractable but sacrifices some information in the data.

Introduction

Climate change is 'the single biggest health threat facing humanity,'[1] and is expected to have a growing impact on human health through multiple pathways, including more frequent extreme weather events and worsening ambient air pollution.[2] Air pollution is currently among the top five modifiable contributors to death and disease globally.[3] The impacts of air pollution, specifically fine particulate matter ($PM_{2.5}$), on the cardiovascular system are well-established. $PM_{2.5}$ exposure has been linked to increased risk of stroke, myocardial infarction, heart failure, venous thromboembolism, and other cardiovascular events.[4-11] More than half of deaths attributable to air pollutants are due to cardiovascular thromboembolic (CTE) events.[12] Epidemiological assessments in this area are also supported by cellular/toxicological experiments and by controlled animal/human studies, which both demonstrate the mechanisms by which $PM_{2.5}$ may trigger acute events as well as prompt the chronic development of cardiovascular diseases.[13]

One of the most vulnerable populations, older adults, are at elevated risk for mortality and morbidity from $PM_{2.5}$, particularly those with accessory comorbidities such as respiratory and cardiovascular diseases.[14] Older adults are also at increased risk for CTE from certain medications taken to treat or prevent comorbidities.[15,16] For example, systemic corticosteroids used for asthma/COPD exacerbations and to treat autoimmune diseases have direct vasoconstriction effects that inhibit fibrinolytic activity of the blood, leading to clinically-recognized thrombogenicity.[17] Further, systemic corticosteroids can cause sodium and fluid retention issues, leading to hypertension or heart failure exacerbations.[18-20]

Although the independent effects of air pollution and corticosteroids on CTE are well-known, no prior study has assessed the risk of both exposures simultaneously on CTE. Thus, it is unknown whether there is a synergy between these factors. Leveraging rich healthcare utilization data on a large cohort of Medicare beneficiaries with comorbidities linked to residential $PM_{2.5}$ concentrations, we examined whether simultaneously experiencing elevated $PM_{2.5}$ concentrations and being exposed to corticosteroid therapies leads to an increased risk of CTE that is greater than the combination of these two effects independently. To our knowledge this is the first study to examine interactions between a drug and an air pollution exposure. We therefore provide a causal inference analytic framework that enables robust investigation of the contributing factors that explain individual-specific vulnerabilities to air pollution through the evaluation of additive interactions in survival models. Additionally, our analyses adjust for a large set of individual-level potential confounders that are typically unmeasured in

environmental health analyses with large claims datasets, which lends added credibility to our findings.

Methods

Study Population and Cohort Definition

The cohort used in this study has been previously described.[14] Briefly, we used data from a 50% random sample of the 2008-2016 Medicare Part D-eligible Fee-for-Service beneficiary population and formed a cohort of individuals with conditions known to increase the risk of CTE. These high-risk conditions included pre-existing cardiovascular diseases, prior venous thromboembolism, total joint arthroplasty, and cancer. Any beneficiary who had an inpatient diagnosis/procedure at any position (primary or otherwise) for one or more of the above causes during a one-year baseline period from their date of enrollment into the Medicare Fee-for-Service system was entered into the cohort at the end of the baseline period. This definition for high CTE risk has been shown to be highly predictive of future CTE events (see Supplemental Table S1 for specific International Classification of Diseases (ICD-9/10) diagnosis codes used to define each high-risk condition). [21]

Outcomes

We followed all participants until they developed one of the outcomes of interest, or until they experienced a censoring event – whichever occurred first. Outcomes of interest included hospitalization for: 1) myocardial infarction or acute coronary syndrome (MI/ACS); 2) ischemic stroke or transient ischemic attack (Stroke/TIA); 3) heart failure (HF); 4) atrial fibrillation (Afib); 5) venous thromboembolism (VTE); or 6) death from any cause (see Supplemental Table S2 for ICD-9/10 diagnosis and procedure codes identifying the outcomes). Non-administrative censoring events included death (when death was not the outcome under study), loss of eligibility for Medicare Part D, and the participant's moving to a ZIP-code without available $PM_{2.5}$ exposure data. We also censored participants after the discontinuation of their first corticosteroid therapy, with a 30-day grace period.

$PM_{2.5}$ Exposures

Seasonal-average $PM_{2.5}$ concentrations were derived from spatially and temporally aggregated predictions from a well-validated, high-resolution $PM_{2.5}$ model.[22] This model predicts $PM_{2.5}$ concentrations at 1-km square grids across the US and consists of an ensemble of neural net

and machine learning sub-models trained on integrated high-resolution satellite, land use, emissions, ground monitoring, and weather data. Daily gridded estimates were aggregated and linked to participants by residential ZIP-code, and then averaged within seasons. Figure 1 demonstrates the significant between-season variation in $PM_{2.5}$ patterns in the US, which motivated our choice to examine seasonal-average $PM_{2.5}$ exposures rather than more traditional yearly-average exposures as shorter-term increases in exposure may have harmful effects in this vulnerable population. We are particularly focused on contrasting outcomes under $PM_{2.5}$ exposures of 12 µg/m^3 vs. 8 µg/m^3, which are policy-relevant thresholds currently in review by the US Environmental Protection Agency (EPA; 12 µg/m^3 being the current US limit for annual average $PM_{2.5}$).[23] We also compare outcomes for the contrast between $PM_{2.5}$ levels of 10 µg/m^3 vs. 5 µg/m^3 in a secondary analysis, informed by the WHO's updated guidelines recommending an annual average limit of 5 µg/m^3 (recently reduced from 10 µg/m^3).[24]

Corticosteroid Exposures

We used Medicare Part D drug dispensing data to identify systemic corticosteroid exposure. Systemic corticosteroids of interest included Cortisone, Hydrocortisone, Prednisone, Prednisolone, Methylprednisolone, Triamcinolone, Dexamethasone, and Betamethasone. Initiation and duration of each corticosteroid were estimated based on the dispensing date, dispensing dose, and days' supply of the participants' prescriptions. Because allowing for continuous follow-up was computationally infeasible, corticosteroid therapy status was updated quarterly until one of the study endpoints was achieved for each participant.

To ensure that individuals' quarterly follow-up times aligned with key dates of corticosteroid usage, we constructed unique drug exposure panels for each cohort member. The anchor point of the drug exposure panels is the date of initiation of corticosteroid therapy during follow-up for users. In other words, for a participant who uses corticosteroids at some point during follow-up, the first day of their corticosteroid therapy always coincides with the first day of a quarter. We then constructed individual-specific panels spanning quarterly intervals extending backward in time to the participant's index date and forward in time to the participant's end date (see Supplemental Figure S1 for example). For individuals who never use corticosteroids during follow-up, quarter start times coincide with changes in season.

Covariates

We identified individual-level sociodemographic characteristics, comorbidities and health services utilization information derived from Medicare enrollment files and inpatient, outpatient, and drug dispensing data from files pertaining to Medicare Parts A, B, and D, respectively. Using Medicare enrollment files, we extracted the following individual-level baseline variables: age, sex, race/ethnicity, and Medicaid eligibility (a proxy for low-income status). Various pre-enrollment measurements were assessed based on diagnosis codes for inpatient and outpatient visits during each participant's baseline period (see Table S3 for complete list of comorbidities). We also derived metrics of health services utilization during the baseline period, including the number of hospitalizations, number of emergency department visits, number of outpatient visits, and number of generic medications dispensed. We consider this collection of variables as time-invariant and treat them as potential confounders between corticosteroid use and CTE.

Additional temporal and neighborhood-level features were also identified to enable further confounding adjustment, for both $PM_{2.5}$-CTE and corticosteroid-CTE associations. These variables included season, year, region, and $PM_{2.5}$ from the prior four seasons as well as area-based measures of population density, proportion of residents living below the federal poverty line, proportion of housing units that are owner-occupied, median home value, median household income, proportion of residents identifying as Hispanic, proportion of residents identifying as Black, and proportion of residents 25+ with at least a college degree that were linked to Medicare by ZIP-code of beneficiaries' residence. These demographic and socioeconomic features were considered as time-varying covariates updated yearly. We also accounted for ZIP-code changes that occur during follow-up and updated participants' $PM_{2.5}$ exposures and neighborhood features accordingly.

Statistical Analysis

We first described summary measures of the individual- and neighborhood-level characteristics and calculated the number of person-years at risk, number of events, and event rates per 1,000 person years for each of the six outcomes examined, both overall and stratified by corticosteroid status. We then fitted history-adjusted marginal structural Cox proportional hazard models, facilitated by estimated inverse probability weights (IPWs), to investigate both the independent and synergistic effects of $PM_{2.5}$ and corticosteroid use on the CTE outcomes.[25,26] Separate models were used to estimate the IPWs for each of the outcomes considered, and separate weighted Cox models were fit over the age-time scale.[27] We included penalized spline

components in the weighted Cox models to account for potential nonlinear effects of $PM_{2.5}$, in addition to a main effect for corticosteroid use and an interaction between corticosteroid use and $PM_{2.5}$ (the penalized spline representation). Given that our cohort comprises individuals with diverse diseases each potentially affecting thrombosis risk, we employed stratification in the Cox models based on disease indication. Particularly, we allowed for disease-specific baseline hazards for autoimmune diseases and COPD/asthma (see Table S4 for ICD-9/10 codes), as these two categories of diseases exhibit unique pathways for cardiovascular and thromboembolic events independent of corticosteroid therapy.[28-33]

The final IPW for a given participant and follow-up period was constructed as the product of three distinct IPWs accounting for different potential sources of bias: an inverse probability of treatment weight for each of the $PM_{2.5}$ and corticosteroid exposures, to adjust for confounding, and an inverse probability of censoring weight to account for informative censoring. The ZIP-code and season-specific IPWs for $PM_{2.5}$ were constructed by taking the inverse of estimated generalized propensity scores modeled using gradient boosting regression. The individual-level IPWs for the quarterly corticosteroid use indicators were obtained by inverting propensity scores estimated using gradient boosting classification. Additionally, over the same corticosteroid use quarters, we modeled the probability of censoring with gradient boosting classification to produce inverse probability of censoring weights. The three IPWs were stabilized by the marginal probabilities of treatment/censoring. Extreme weights were truncated at the 1st and 99th percentiles of the final IPW distribution (see Supplement for additional details on the construction of the IPWs).

We report the hazard ratio estimates and 95% confidence intervals associating $PM_{2.5}$ with the five CTE outcomes and all-cause mortality (comparing average hazards evaluated at $PM_{2.5}$ levels of 12 vs. 8 $\mu g/m^3$ and 10 vs. 5 $\mu g/m^3$) with corticosteroid status held fixed (both on and off treatment). We also provide hazard ratios associating corticosteroid use with each outcome, with $PM_{2.5}$ held fixed at 8 $\mu g/m^3$. We assessed synergy between $PM_{2.5}$ and corticosteroids by calculating the relative excess risk due to interaction (RERI) – a measure of interaction on the additive scale that can be interpreted as the relative increase in risk due to the combined effect of the two exposures versus the individual effects of the two exposures summed together (presented as a percentage).[34-37] Cluster m-out-of-n bootstrap samples of the Cox model parameters were used to compute standard errors for the RERI which account for the correlation between units in the same ZIP-code while maintaining adequate computational efficiency.[38,39] Additional details for estimating the RERI are provided in the Supplement.

This study was approved by the Institutional Review Board of Rutgers University. All analyses were conducted using R version 4.2.0. Data cleaning was performed using SAS version 9.4.

Patient and public involvement: Patients and/or the public were not involved in the design, conduct, reporting, or dissemination of this research.

Results

The cohort included 1,936,786 beneficiaries with a total of 4,629,432 person-years of follow-up. Average age at index date was 76.8 years, with 60.0% of cohort members female, 15.9% Medicaid eligible, 87.4% White, and 8.2% Black (Table 1). The average participant follow-up time was 2.4 ± 2.3 years, although this figure along with the total person-years of follow-up fluctuates depending on the outcome being evaluated (Supplemental Table S5). Among the Medicare beneficiaries evaluated, 37.7% had at least one prescription for corticosteroid therapy during follow-up. Participants who received corticosteroid therapy were slightly younger than those who never received corticosteroid therapy (75.7 versus 77.4 years old), were more likely to be White (89.8% versus 85.9%) and were less likely to be Medicaid eligible (14.0% versus 17.0%). Table 1 and Supplemental Table S3 shows summary statistics of several comorbidities included into the IPW models, stratified by disease indications listed in Table S4. Table 2 contains data on demographics and season-specific $PM_{2.5}$ measurements over 329,544 ZIP-code years from 35,695 unique ZIP-codes. The average $PM_{2.5}$ level was 8.3 ± 2.4 μg/m^3, average population density was 1,425 people per square mile, and the overall poverty rate was 10.3%.

During an average follow-up of 2.4 years per person, we observed a total of 244,451 hospitalization for HF, 118,754 hospitalizations for Afib, 101,611 hospitalizations for Stroke/TIA, 93,191 hospitalizations for MI/ACS, 41,635 hospitalizations for VTE, and 491,445 deaths. The incidence rates per 1,000 person-years were 57.1 for HF, 27.0 for Afib, 22.8 Stroke/TIA, 20.8 for MI/ACS, 9.1 for VTE, and 106.2 for death (Supplemental Table Table S5).

Corticosteroid use was associated with higher risks of CTE and death, with significant associations for all six outcomes examined. Holding $PM_{2.5}$ fixed at 8 μg/m^3, the hazard ratios (95% CI) for corticosteroid use were 2.04 (1.94, 2.14) for MI/ACS, 1.51 (1.42, 1.61) for Stroke/TIA, 2.18 (2.11, 2.25) for HF, 3.39 (3.19, 3.61) for VTE, 2.25 (2.11, 2.40) for Afib, and 2.64 (2.57, 2.72) for Death.

Seasonal-average PM$_{2.5}$ exposure was also significantly associated with an increased risk of each of the six CTE and mortality outcomes. Increasing the PM$_{2.5}$ concentration from 8 μg/m^3 to 12 μg/m^3, in the absence of corticosteroid therapy, resulted in hazard ratios (95% CI) of 1.244 (1.226, 1.263) for MI/ACS, 1.252 (1.234, 1.271) for Stroke/TIA, 1.336 (1.323, 1.349) for HF, 1.307 (1.278, 1.337) for VTE, 1.181 (1.163, 1.200) for Afib, and 1.227 (1.218, 1.236) for Death. Figure 2 contains the estimated hazard ratios associated with increasing PM$_{2.5}$ from 5 μg/m^3 to 10 μg/m^3 and the estimated PM$_{2.5}$ hazard ratios while receiving corticosteroid therapy.

Evaluating the interactions between PM$_{2.5}$ and corticosteroid use on the additive scale, we observed significant interactions (RERI [95% CI]) associated with increasing PM$_{2.5}$ from 8 μg/m^3 to 12 μg/m^3 for HF (15.6% [4.0%, 27.3%]), with a borderline significance interaction detected for death (12.5 [-0.6%, 25.5%]). Increasing PM$_{2.5}$ from 5 μg/m^3 to 10 μg/m^3 resulted in a significantly increased excess risk due to interaction (RERI [95% CI]) for HF (32.4% [14.9%, 49.9%]) and MI/ACS (29.8% [5.5%, 54.0%]). Figure 3 plots the RERI curves corresponding to various PM$_{2.5}$ contrasts across the range of observed exposure levels for each outcome. For most outcomes, the increase in RERI is steepest when PM$_{2.5}$ is less than 10 μg/m^3, indicating more intense synergy between PM$_{2.5}$ and corticosteroids even at PM$_{2.5}$ concentrations below current US annual average PM$_{2.5}$ standards.

An interesting result worth noting concerns the hazard ratios associated with PM$_{2.5}$ while receiving corticosteroid therapy. Observe that nearly every estimate of the hazard ratio in the third subplot of Figure 2 is attenuated toward the null value of one relative to the second subplot in Figure 2 examining the effects of PM$_{2.5}$ while not receiving corticosteroid therapy. This implies that the multiplicative interaction between PM$_{2.5}$ and corticosteroid use is negative. Thus, our results provide an example of the discordance that can occur between additive and multiplicative measures of synergy, which is well-established in the literature, and further demonstrates the caution one needs to consider when evaluating potential causal interactions.[40]

Discussion

In this study, we examined the interaction between seasonal-average PM$_{2.5}$ exposure and corticosteroid use on the risk of CTE in a cohort of Medicare beneficiaries with high-risk conditions for CTE from the broadly generalizable set of Fee-for-Service enrollees. Using marginal structural models from the causal inference literature, which adjust for time-varying confounding attributable to several observed neighborhood- and individual-level covariates, we found that the escalation in risk for certain CTE outcomes during periods of simultaneous high

PM$_{2.5}$ exposure and corticosteroid use was larger than what would be expected from the independent effects of the two factors added together. In particular, we detected synergism between these two exposures for heart failure and myocardial infarction/ACS.

Numerous studies have reported that older adults and those with comorbidities, particularly respiratory and cardiovascular disease,[41] are at elevated risk for mortality and morbidity from air pollution. Older adults may be more vulnerable not only because of age and pre-existing diseases, but also because of the multiple medications they receive.[42] Despite making up only 13% of the US population, older adults account for more than one-third of all prescriptions dispensed.[43,44] Yet, current evidence on the health impacts of air pollution lacks consideration of additional factors to characterize individuals at risk.[40,45] In particular, studies lack considerations for medication use, a prevalent risk factor that may further increase vulnerability in older adults. To our knowledge, our study provides the first epidemiologic evidence of synergistic effects of air pollution and medication on CTE outcomes in older adults.

In addition, examining the independent effects of PM$_{2.5}$ and corticosteroid use on CTE and mortality, we observed results that corroborate those already found in the current literature. PM$_{2.5}$ has been significantly associated with increased risk of MI/ACS,[6] Stroke/TIA,[7] HF,[46] VTE,[14] Afib,[5] and all-cause mortality.[47] Our results sometimes yielded associations larger in magnitude than those found in previous studies. This is unsurprising given that our cohort consists only of participants already at high-risk for CTE.[14] Likewise, corticosteroid use was strongly and significantly associated with increased risk of the five CTE outcomes and all-cause mortality in our study. The deleterious effects that corticosteroids can have on CTE outcomes have already been described in several other reports.[19,20]

There are several potential biological mechanisms explaining the synergistic interactions between prescription systemic corticosteroids and PM$_{2.5}$ on CTE. First, both PM$_{2.5}$ and glucocorticoids have been shown to induce hypercoagulable states in humans. As PM$_{2.5}$ is small enough to translocate into the bloodstream, chronic PM$_{2.5}$ exposure may increase coagulability indirectly through production of pro-oxidative and pro-inflammatory factors that can then induce production of coagulation factors and fibrinogen. Steroids may complement this thrombogenicity by stimulating Plasminogen Activator Inhibitor-1, which decreases dissolution of fibrinogen.[48] Second, PM$_{2.5}$ may also lead to atherosclerotic changes and autonomic cardiac dysfunction (i.e., reduced heart rate variability), which in conjunction with adverse metabolic changes seen with systemic glucocorticoid use, can increase risk of cardiovascular disease-related outcomes.

Third, both PM$_{2.5}$ inhalation[49] and glucocorticoids[50] have been shown to have vasoconstrictive effects, which can increase blood pressure, risk of hypoxia in cardiac/brain tissue, and ultimately lead to MI or stroke. Some steroids also exhibit mineralocorticoid activity at higher doses which can lead to fluid retention and potassium efflux.[51] In combination with PM$_{2.5}$'s effects on autonomic dysfunction and modulation of vascular tone,[52] this could potentially exacerbate heart failure or induce arrhythmias.

Our analysis is not without its limitations. First, using model-based PM$_{2.5}$ aggregated to ZIP-codes carries the potential for attenuation created by exposure measurement error.[53] However, even with such potential attenuation, we still obtained significant results. Second, comorbidities were captured and fixed at the index date and not allowed to vary over time. However, most comorbidities that we accounted for are chronic diseases that are rarely reversed. Third, we censored participants after their first corticosteroid therapy ended, and repeated corticosteroid exposure was not considered in the analyses. A recurrent events model might have been constructed to alleviate this issue; however, fitting marginal structural models in this design is both more time-intensive and new to the causal inference space. Moreover, our approach to consider the first course of exposure makes epidemiological sense given that repeated drug exposures are likely to be associated with worsening of the disease or comorbidities, which is difficult to correct for in a model of the exposure responses.[54] Fourth, exposure to PM2.5 may contribute to the development of diseases that necessitate corticosteroid therapies, such that corticosteroids may mediate the overall impact of PM2.5. However, in this paper we did not specifically assess this role of corticosteroids as a potential mediator of PM2.5 effects. Instead, our focus was on examining the combined effects of PM2.5 and corticosteroid use. Finally, while we allowed for differing baseline risks of the outcomes for certain disease indications, we did not investigate the potential differential exposure effects experienced by distinct groups of patients using corticosteroids. Based on the findings of this initial analysis, further investigation of these heterogeneous effects is necessary in future studies.

Conclusion

Using a cohort of nearly two million adults at high-risk for CTE, we found evidence of a synergistic effect between seasonal PM$_{2.5}$ exposure and corticosteroid use on several CTEs. We used advanced causal inference methods to control for potential confounding attributable to a large set of individual- and neighborhood-level covariates. We also observed strong independent impacts of PM$_{2.5}$ and corticosteroids on each of the six outcomes examined. Our

study demonstrates that certain combinations of medication and $PM_{2.5}$ can work synergistically to impose increased health risks on older adults, even when $PM_{2.5}$ concentrations fall below EPA standards. While our results should not discourage clinicians/older adults from prescribing/taking medications needed for treatment, they do shape our conceptual model of disease risk, which we believe should incorporate potential synergisms between individual- and environmental-level risk factors. Our results also emphasize the need for stricter control of $PM_{2.5}$ concentrations to help protect these vulnerable populations for whom corticosteroid medications are commonly indicated.

Contributors: KPJ, RCN, and SS conducted the analysis, interpreted the data, and drafted the article. AV, BB, AP, and DR were responsible for writing portions of the literature review and aided in drafting the introduction and discussion of the article, particularly the clinical consequences of the results. PG, AP, and MR were responsible for preprocessing and collating the data, along with other data management and administrative duties. SS guided and supervised the research process. RCN and SS provided funding support. All authors provided critical feedback on the study design and revised the manuscript. All authors approved the final draft of the manuscript and are accountable for all aspects of the work reported herein.

Competing interests: The authors have no financial or social conflicts of interest to declare.

Funding: This study was supported by National Institutes of Health grants R01AG060232, 1K01ES032458, and 5T32ES007142.

Data availability statement: For data privacy reasons, the Medicare data used in this study cannot be made publicly available, but interested parties can request access by applying through the US Centers for Medicare and Medicaid Services. The $PM_{2.5}$ exposure data are publicly available at the following link: https://doi.org/10.7927/0rvr-4538. Area-level covariates used herein are also publicly available from the US Census Bureau website. Code for fitting the models, plotting estimates, and reproducing study findings reported within this manuscript is available at: https://github.com/kevjosey/pm-steroid.

Ethics approval: The study was approved by the Rutgers Institutional Review Board (ID Pro20170001685).

References

1. World Health Organization. COP26 Special Report on Climate Change and Health: The Health Argument for Climate Action. World Health Organization; 2021. https://www.who.int/publications/i/item/9789240036727

2. U.S. Environmental Protection Agency. Climate Change and Social Vulnerability in the United States: A Focus on Six Impacts. U.S. Environmental Protection Agency, 430-R-21-003; 2021.

3. Murray, Christopher J L et al. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study. *The Lancet*. 2019;396(10258):1223-1249.

4. Danesh Yazdi M, Wang Y, Di Q, et al. Long-term exposure to PM2.5 and ozone and hospital admissions of Medicare participants in the Southeast USA. *Environ Int*. 2019;130:104879.

5. Danesh Yazdi M, Wang Y, Di Q, et al. Long-Term Association of Air Pollution and Hospital Admissions Among Medicare Participants Using a Doubly Robust Additive Model. *Circulation*. 2021;143(16):1584-1596.

6. Dominici F, Peng RD, Bell ML, et al. Fine Particulate Air Pollution and Hospital Admission for Cardiovascular and Respiratory Diseases. *JAMA*. 2006;295(10):1127-1134.

7. Kioumourtzoglou MA, Schwartz JD, Weisskopf MG, et al. Long-term PM2.5 Exposure and Neurological Hospital Admissions in the Northeastern United States. *Environ Health Perspect*. 2016;124(1):23-29.

8. Rhee J, Dominici F, Zanobetti A, et al. Impact of Long-Term Exposures to Ambient PM2.5 and Ozone on ARDS Risk for Older Adults in the United States. *Chest*. 2019;156(1):71-79.

9. Shi L, Wu X, Danesh Yazdi M, et al. Long-term effects of PM2·5 on neurological disorders in the American Medicare population: a longitudinal cohort study. *Lancet Planet Health*. 2020;4(12):e557-e565.

10. Yitshak-Sade M, Bobb JF, Schwartz JD, et al. The association between short and long-term exposure to PM2.5 and temperature and hospital admissions in New England and the synergistic effect of the short-term exposures. *Sci Total Environ*. 2018;639:868-875.

11. Zanobetti A, Franklin M, Koutrakis P, Schwartz J. Fine particulate air pollution and its components in association with cause-specific emergency admissions. *Environ Health*. 2009;8(1):58.

12. Landrigan PJ. Air pollution and health. *Lancet Public Health*. 2017 Jan;2(1):e4-e5. Erratum in: *Lancet Public Health*. 2017 Feb;2(2):e73

13. Rajagopalan S, Al-Kindi SG, Brook RD. Air Pollution and Cardiovascular Disease: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2018;72(17):2054-2070.

14. Nethery RC, Josey K, Gandhi P, et al. Air Pollution and Cardiovascular and Thromboembolic Events in Older Adults with High-Risk Conditions. *Am J Epidemiol*. 2023:kwad089. Epub ahead of print.

15. Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. *Heart*. 2004;90(8):859-865.

16. Johannesdottir SA, Horváth-Puhó E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. *JAMA Intern Med*. 2013;173(9):743-752.

17. Majoor CJ, Sneeboer MM, de Kievit A, et al. The influence of corticosteroids on hemostasis in healthy subjects. *J Thromb Haemost*. 2016;14(4):716-723.

18. Mebrahtu TF, Morgan AW, West RM, et al. Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study. *CMAJ*. 2020;192(12):E295-E301.

19. Fardet L, Fève B. Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. *Drugs*. 2014;74(15):1731-1745.

20. Ng MK, Celermajer DS. Glucocorticoid treatment and cardiovascular disease. *Heart*. 2004;90(8):829-830.

21. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated with Rosiglitazone or Pioglitazone. *JAMA*. 2010;304(4):411-418.

22. Di Q, Amini H, Shi L, et al. An ensemble-based model of PM2.5 concentration across the contiguous United States with high spatiotemporal resolution. *Environ Int.* 2019;130:104909.

23. US Environmental Protection Agency, Office of Air Quality Planning and Standards, Health and Environmental Impacts Division. Policy Assessment for the Reconsideration of the National Ambient Air Quality Standards for Particulate Matter. Environmental Protection Agency; 2022. https://www.epa.gov/system/files/documents/2022-05/Final%20Policy%20Assessment%20for%20the%20Reconsideration%20of%20the%20PM%20NAAQS_May2022_0.pdf

24. World Health Organization. *WHO global air quality guidelines: particulate matter (PM2.5 and PM10), ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide*. World Health Organization; 2021. https://apps.who.int/iris/handle/10665/345329. License: CC BY-NC-SA 3.0 IGO

25. Neugebauer R, van der Laan MJ, Joffe MM, Tager IB. Causal inference in longitudinal studies with history-restricted marginal structural models. *Electron J Stat*. 2007;1:119-154.

26. Petersen ML, Deeks SG, Martin JN, van der Laan MJ. History-adjusted Marginal Structural Models for Estimating Time-varying Effect Modification. *Am J Epidemiol*. 2007;166(9):985-993.

27. Pencina MJ, Larson MG, D'Agostino RB. Choice of time scale and its effect on significance of predictors in longitudinal studies. *Stat Med*. 2007;26(6):1343-1359.

28. Tattersall MC, Guo M, Korcarz CE, et al. Asthma predicts cardiovascular disease events: the multi-ethnic study of atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2015;35(6):1520-5.

23. Zöller B, Pirouzifard M, Memon AA, et al. Risk of Pulmonary embolism and deep venous thrombosis in patients with asthma: A nationwide case-control study from Sweden. *European Respiratory Journal*. 2017;49(2):1601014.

30. Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons?. *European Respiratory Review*. 2018;27(149):180057.

31. Shetty R, Seddighzadeh A, Piazza G, Goldhaber SZ. Chronic obstructive pulmonary disease and deep vein thrombosis: a prevalent combination. *Journal of Thrombosis and Thrombolysis*. 2008;26:35-40.

32. Crowson CS, Liao KP, Davis III JM, et al. Rheumatoid arthritis and cardiovascular disease. *American Heart Journal*. 2013;166(4):622-8.

33. Al-Homood IA. Thrombosis in systemic lupus erythematosus: a review article. *International Scholarly Research Notices*. 2012;2012:428269.

34. Li R, Chambless L. Test for additive interaction in proportional hazards models. *Ann Epidemiol*. 2007;17(3):227-236.

35. Knol MJ, VanderWeele TJ, Groenwold RH, et al. Estimating measures of interaction on an additive scale for preventive exposures. *European Journal of Epidemiology*. 2011;*26*(6):433-438.

36. VanderWeele TJ. Causal interactions in the proportional hazards model. *Epidemiology*. 2011;22(5):713-717.

37. Knol MJ, van der Tweel I, Grobbee DE, et al. Estimating interaction on an additive scale between continuous determinants in a logistic regression model. *Int J Epidemiol*. 2007;36(5):1111-1118.

38. Mathur MB, VanderWeele TJ. R Function for Additive Interaction Measures [published correction appears in *Epidemiology*. 2019 Jul;30(4):e30]. *Epidemiology*. 2018;29(1):e5-e6.

39. Josey KP, Delaney SW, Wu X, et al. (2023). Air Pollution and Mortality at the Intersection of Race and Social Class. N Engl J Med. 2023;388(15):1396-1404.

40. VanderWeele TJ, Knol MJ. A tutorial on interaction. *Epidemiologic Methods*. 2014;3(1):33-72.

41. Sacks JD, Stanek LW, Luben TJ, et al. Particulate Matter–Induced Health Effects: Who Is Susceptible? *Environmental Health Perspectives*. 2011;119(4):446–54.

42. Ajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. *Am J Geriatr Pharmacother*. 2007;5:345-51.

43. McCloskey A. Cost overdose: Growth in drug spending for the elderly, 1992-2010. Families USA Foundation; 2000.

44. World Health Organization. Ambient air pollution: a global assessment of exposure and burden of disease. World Health Organization; 2016. https://apps.who.int/iris/handle/10665/250141

45. Brook RD. Cardiovascular effects of air pollution. *Clin Sci (Lond)*. 2008;115:175-87.

46. Shah AS, Langrish JP, Nair H, et al. Global association of air pollution and heart failure: a systematic review and meta-analysis. *The Lancet*. 2013;382(9897):1039-48.

47. Di Q, Wang Y, Zanobetti A, et al. Air Pollution and Mortality in the Medicare Population. *N Engl J Med*. 2017;376(26):2513-2522.

48. van Zonneveld AJ, Curriden SA, Loskutoff DJ. Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. *Proc Natl Acad Sci U S A*. 1988;85(15):5525-5529.

49. Brook RD, Brook JR, Urch B, et al. Inhalation of fine particulate air pollution and ozone causes acute arterial vasoconstriction in healthy adults. *Circulation*. 2002;105(13):1534-6.

50. Yang S, Zhang L. Glucocorticoids and vascular reactivity. *Curr Vasc Pharmacol*. 2004;2(1):1-12.

51. van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. *Arch Intern Med*. 2006;166(9):1016-20.

52. Link MS, Dockery DW. Air pollution and the triggering of cardiac arrhythmias. *Curr Opin Cardiol*. 2010;25(1):16-22.

53. Josey KP, deSouza P, Wu X, et al. Estimating a Causal Exposure Response Function with a Continuous Error-Prone Exposure: A Study of Fine Particulate Matter and All-Cause Mortality. *J Agric Biol Environ Stat*. 2023 Mar;28(1):20-41.

54. Pazzagli L, Linder M, Zhang M, et al. Methods for time-varying exposure related problems in pharmacoepidemiology: An overview [published correction appears in Pharmacoepidemiol Drug Saf. 2018 Mar;27(3):356]. *Pharmacoepidemiol Drug Saf*. 2018;27(2):148-160.

Tables and Figures

Table 1. Characteristics of high-risk Medicare beneficiaries (total N=1,936,786). Beneficiaries are further divided into strata of those who received at least one dispensing of systemic corticosteroid during follow-up and those who never received corticosteroids during follow-up. We report counts (%) for categorical variables and mean ± standard deviation for continuous variables.

Variable	Level	All Participants (N = 1,936,786)	Participants with Autoimmune Diseases (N = 212,697)	Participants with COPD or Asthma(N = 510,941)
Age at Index		76.8 ± 8.0	75.9 ± 7.2875.7 ± 7.3	76.5 (7.7)77.4 ± 8.3
Male		774,852 (40.0)	280,471 (38.4)	494,381 (41.0)
Race				
	White	1,692,791 (87.4)	183,623 (86.3)655,493 (89.8)	449,203 (87.9)1,037,298 (85.9)
	Black	159,001 (8.2)	47,725 (6.5)	111,276 (9.2)
	Hispanic	35,508 (1.8)	10,571 (1.5)	24,937 (2.1)
	Asian	24,152 (1.3)	7,334 (1.0)	16,818 (1.4)
	North American Native	6,943 (0.4)	2,489 (0.3)	4,454 (0.4)
	Other	18,391 (1.0)	5,934 (0.8)	12,457 (1.0)
Medicaid Eligibility		307,985 (15.9)	29,050 (13.6)	205,734 (17.0)
Chronic Conditions				
	Total Hip Arthroplasty	231,114 (11.9)	30,939 (14.6)81,194 (11.1)	54,452 (10.7)149,920 (12.4)
	Total Knee Arthroplasty	473,206 (24.4)	186,349 (25.5)	286,857 (23.8)
	Acute Coronary Syndrome	74,783 (3.9)	33,651 (4.6)	41,132 (3.4)

	Cancer	291,014 (15.0)	116,892 (16.0)	174,122 (14.4)
	Atrial Fibrillation	595,876 (30.8)	219,836 (30.1)	376,040 (31.2)
	Hemorrhagic Stroke	184,442 (9.5)	61,232 (8.4)	123,210 (10.2)
	Heart Failure	291,993 (15.1)	102,930 (14.1)	189,063 (15.7)
	Ischemic Stroke	175,201 (9.1)	58,686 (8.0)	116,515 (9.6)
	Myocardial Infarction	127,147 (6.5)	43,605 (6.0)	83,542 (6.9)
	Peripheral Vascular Disease	196,055 (10.1)	73,127 (10.0)	122,928 (10.2)
	Transient Ischemic Attack	56,930 (2.9)	20,283 (2.8)	36,647 (3.0)
	Venous Thromboembolism	95,081 (4.9)	36,938 (5.1)	58,143 (4.8)
	Cerebrovascular Accident	184,442 (9.5)	61,232 (8.4)	45,901 (9.0)
	Carotid Stenosis	828 (0.0)	117 (0.0)	304 (0.1)
Hospitalization and Medication History				
	Prior Inpatient Hospitalizations	1.7 ± 1.3	1.8 ± 1.41.7 ± 1.3	2.0 ± 1.71.7 ± 1.3
	Prior ER Visits	0.8 ± 1.2	0.8 ± 1.2	0.8 ± 1.2
	Prior Outpatient Visits	8.3 ± 9.2	8.8 ± 9.5	8.0 ± 9.1
	Prior Medications Dispensed	12.1 ± 7.1	13.5 ± 7.2	11.2 ± 7.0

Table 2. Neighborhood-level characteristics averaged over 329,727 ZIP-code years across 35,695 unique ZIP-codes.

Variable	Level	Mean ± SD
PM$_{2.5}$ (µg/m^3)		
	Yearly Average	8.3 ± 2.4
	Winter	8.7 ± 3.4
	Spring	7.8 ± 2.4
	Summer	9.5 ± 2.9
	Fall	7.5 ± 2.4
Population Density (per mile^2)		1,425.0 ± 4,978.5
Median House Value ($)		180,117.4 ± 154,630.3
Median Household Income ($)		52,276.7 ± 22,549.9
% Poverty		10.3 ± 10.7
% Owner Occupied Housing		72.3 ± 17.4
% Hispanic		9.7 ± 17.1
% Black		8.5 ± 16.5
% White		82.9 ± 20.8
% less than High School		23.5 ± 16.8

Figure 1. Season-specific average PM₂.₅ measurements for every ZIP-code across the United States over the period 2008-2016. Note that the PM₂.₅ measurements are most severe in the Southern states during the Summer and in the upper-Midwest states during Winter.

Figure 2. Hazard ratios (and 95% confidence intervals) for corticosteroid use and increasing PM$_{2.5}$ while both on and off corticosteroids. We contrasted the effects of setting PM$_{2.5}$ concentrations to 10 vs. 5 µg/m^3 and 12 vs. 8 µg/m^3 which were chosen based on WHO and EPA guidelines.[23,24]

Figure 3. Relative excess risk due to interaction (RERI) between PM$_{2.5}$ and corticosteroid usage for each of the six outcomes (and their 95% confidence interval bands), comparing a range of PM$_{2.5}$ concentrations to reference values of 5 µg/m^3 (salmon) and 8 µg/m^3 (blue). Curves represent the change in RERI due to simultaneously initiating corticosteroid treatment and increasing PM$_{2.5}$ exposure to any given level above the corresponding PM$_{2.5}$ reference level. Note that the curves intersect zero at their respective reference levels, as there can be no excess risk increase due to the interaction without changing both exposures concomitantly.